IVIG Versus Plasmapheresis in the Treatment of Guillian Barrie Syndrome Patients
Status:
Recruiting
Trial end date:
2022-03-30
Target enrollment:
Participant gender:
Summary
In this study, the investigators address the question: whether treatment with IVIG is
superior to treatment using plasmapheresis for functional recovery of patients with GBS?
Recovery was quantified using: The changes in the A-Clinical grading scale MRC ( medial
research council sum score ) and B-overall neuropathy limitations scale as the primary
outcome and the changes in Neurophysiological study 3 months after treatment as a secondary
outcome.
This information will be used to evaluate which treatment is more beneficial to GBS patients.